Products&Pipeline
CT IDBrief Title
NCT04965337Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects
NCT04843449Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
NCT04845646DDI Study of ASC41 Tablets in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
NCT04527250A Study of the Relative Bioavailability of ASC41 in Healthy Subjects
NCT04465890A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
NCT04352361Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects
NCT04358523A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers
NCT04686994Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
NCT04692025Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers
NCT04547894A Study of the Pharmacokinetics of ASC09F in Healthy Subjects
NCT04679129Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects
NCT03430830A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
NCT03288636Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
NCT03362814Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
NCT03020134Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China
NCT03020082Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
NCT03020095Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
NCT03019991Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China


For more information, please visithttps://www.clinicaltrials.gov/